Alyftrek™ (vanzacaftor/tezacaftor/deutivacaftor) – New orphan drug approval
December 20, 2024 - Vertex announced the FDA approval of Alyftrek (vanzacaftor/ tezacaftor/deutivacaftor), for the treatment of cystic fibrosis (CF) in patients 6 years of age and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.